The Philadelphia (Ph) translocation is responsible for the generation of the chimeric BCR/ABL oncogene. The Ph chromosome constitutes the earliest detectable chromosome abnormality in chronic myelogenous leukemia and is also found in acute lymphoblastic leukemia. Mice transgenic for a PI90 BCR/ABL-producing DNA construct develop lymphoblastic leukemia/lymphoma and provide an opportunity to study early stages of the disease as well as progression. In this study, we have karyotyped the bone marrow of I O 19-day-old BCR/ABL PI90 transgenic mice from a line that reproducibly develops leukemia /lymphoma. Leukemic cells from 17 terminally ill transgenic founders and progeny were HE PHILADELPHIA (Ph) chromosome, specifically
The Philadelphia (Ph) translocation is responsible for the generation of the chimeric BCR/ABL oncogene. The Ph chromosome constitutes the earliest detectable chromosome abnormality in chronic myelogenous leukemia and is also found in acute lymphoblastic leukemia. Mice transgenic for a PI90 BCR/ABL-producing DNA construct develop lymphoblastic leukemia/lymphoma and provide an opportunity to study early stages of the disease as well as progression. In this study, we have karyotyped the bone marrow of I O 19-day-old BCR/ABL PI90 transgenic mice from a line that reproducibly develops leukemia /lymphoma. Leukemic cells from 17 terminally ill transgenic founders and progeny were HE PHILADELPHIA (Ph) chromosome, specifically T found in chronic myelogenous leukemia (CML) and Ph-positive acute lymphoblastic leukemia (ALL), is the result of a reciprocal translocation between chromosomes 9 and 22.'-3 The translocation causes the ABL oncogene from chromosome 9 to fuse with part of the BCR gene located on chromosome 22 . In approximately half of cases of Phpositive ALL this chimeric gene produces a P190 BCR/ ABL fusion protein, containing only those amino acids encoded by the first exon of the BCR gene; in the remaining cases of Ph-positive ALL and in CML a fusion protein with a larger BCR gene contribution, P210, is The oncogenic role of these fusion proteins is suggested by the fact that the Ph chromosome is a consistent abnormality present at the time of diagnosis in the leukemic cells of CML and ALL patients, and also by the oncogenic outcome of transgenic and other in vivo experiments using the BCR/ABL fusion gene?"
Caficer is thought to be a multistep process that passes through different stages, each accompanied by gene mutations.113'2 This process is exemplified by CML. Debate continues as to whether a predisposed leukemic cell, which lacks the Ph chromosome, exists in CML,'"I4 but the Ph chromosome is always found at diagnosis, usually as the sole karyotypic abnormality." With progression of the disease, additional chromosome aberrations are observed in as many as 80% of patients after the transition from chronic to acute ~tage.'~.'' ALL is often accompanied by nonrandom chromosome abnormalities at presentation, among which the Ph chromosome is one of the most frequently seen. 18 To investigate the role of BCR/ABL in leukemia, we have generated mice transgenic for a DNA construct that produces the P190 protein. Eight founder mice rapidly succumbed to leukemia (both myeloid and lymphoid) within a short period (58 days) after birth, demonstrating the leukemogenic activity of the activated ABL oncogene.'O In the present study, we have asked whether the onset and progression of BCR/AEiL P190-generated leukemia in transgenic mice is accompanied by the appearance of chromosome abnormalities such as those found in humans. Our results show a normal karyotype in initial stages and support the assumption that the activated BCR/ABL gene also karyotyped as well as bone marrow transplant recipients of leukemic donor marrow. Karyotypically visible aberrations were absent from the early stages of BCR/ABL P190-generated leukemia and normal metaphases could be found even in the terminal stages of the disease. A high frequency of aneuploidy was found in advanced leukemia, with a marked preference for the gain of mouse chromosomes 12, 14, or 17. These results point to a primary role for BCR/ABL in leukemogenesis and suggest a destabilizing effect of the BCR/ABL gene on the regulation of cell division. 0 1992 by The American Society of Hematology.
alone plays a key role in the development of leukemia. Later stages of the disease are characterized by nonrandom numerical changes of mouse chromosomes that have a genetic analogy to human chromosomes involved in leukemia.
MATERIALS AND METHODS
Transgenic mice were generated as previously described" using a BCRIABL construct encoding the P190 fusion protein. In different lines the transgenic DNA construct is expected to have been integrated independently on different chromosomes. In cases in which the copy number of the transgene was higher than one, integration most often occurs in a tandem, head-to-tail fashion in one particular locus. There is no evidence that integration of transgene DNA into the mouse genome exhibits site-specificity."
Founder animals were the offspring of matings between C57B1/ CBA F, animals. 
Cytvgenetks.
monosomy of a particular chromosome. Heparinized peripheral blood (PB) or BM was collected in RPMI 1640 medium supplemented with 15% fetal bovine serum. PB cells were used only when WBCs were higher than 50 x 109/L; nonleukemic blood and blood containing less lymphoblasts did not yield sufficient metaphases under these culture conditions. Cells were washed once, then incubated with 100 ng/mL colcemid (GIBCO, Grand Island, NY) for 1 hour at 3TC, given a hypotonic shock in 0.075 mol/L KCI for 20 minutes at 3TC, and fixed and washed with cold 1:3 (vol/vol) acetic acidmethanol. Chromosomes were trypsin G-banded according to Seabright.zo Chromosome banding terminology was as described by Nesbitt and Franke?' DNAs were isolated from spleen, lymph nodes, muscle, blood, and kidney as described." DNAs digested with EcoRI were run on 0.7% gels, blotted to nitrocellulose, and hybridized to a 1.2-kb Msp IIEcoRI J, probe. Posthybridization washings were at 0.1X SSC at 65°C. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From RESULTS ne transgenic mice expressing ~1 % B C R /~L described previouslyio all succumbed to leukemia before and progeny was obtained from SOme of these. h i m a i s developed LL and were evaluated karyotypically at different stages of disease.
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K~~~~~~~ oftransgenic BCRIABL p190fou~ermice and theirprogeny. A total of 17 mice were analyzed cytogenetically. Karyotypic findings in leukemic cells isolated in the terminal stages of disease are detailed in Table g and summarized in Table 2 for the three founder animals (nos. 529, 538, and 632) and 14 progeny animals derived from founders no. 632,629,626, and 623;
Abnormal karyotypes were fouhd in 15 of the 17 animals analyzed and ranged from 10% to 100% of metaphase cells scored. Trisomy predominated and was nonrandom with a preference for chromosomes 10,12,14, and 17 ( Table 1 , Fig  2A through E) . Founder animal no. 538 showed a t(12;16). Two of the 17 animals analyzed had normal karyotypes, The first animal (no. 626-729) had a leukemic BM, but lymph nodes and PB were normal. The second animal (no. 623-844-1035) was diagnosed with lymphoblastic lymphoma.
Karyotypically normal cells were found in eight of the animals, even in those mice with a high WBC. For example, mice no. 529, 632-767, and 623-844-1037, all with a WBC above 100 x lo9, had at least 80% normal metaphases ( Table 1) . These high WBCs suggest that the karyotypically normal cells were leukemic.
Nine of the 17 animals showed evidence of clonal evolution. For example, animals no. 623-881 and 623-844 showed normal metaphases as well as two or three abnormal clones, which seem to have been derived through the sequential gain of chromosomes ( Table 1) . There was also evidence of independent clone formation. For example, mouse no. 626-730 had five apparently unrelated abnormal karyotypes, in addition to normal metaphases ( Table 1) . Animal no. 623-844-1051 showed evolution within clones as well as independent clone formation ( Table 1) . BM transplant procedures were used to investigate cytogenetic changes during tumor progression. The transplant strategy is outlined in Fig 1. Survival times were from 16 to 48 days and WBCs were elevated at least fourfold (not shown). Karyotype analysis was performed on material collected at autopsy.
Sublethally irradiated C57B1 X CBA hosts were transplanted with leukemic BM or spleen cells from two different BCR/ABL P190 transgenic mice. BM or splenocytes from founder mouse no. 713 that had ALL were transplanted into four recipients. Two of these recipients, R.l and R.2, developed ALL after 48 and 69 days, respectively. Transplantation of the leukemic cells of R.l to three secondary recipients resulted in the rapid development of disease with death at 15 or 16 days. Serial transfers to tertiary recipients resulted in an increasingly aggressive type of leukemia with a short latency period (9 days; results not shown). c1one Of R*1 and a second c1one with a smdl marker chromosome, the origin of which could not be identqed, but which was identical in all three animals (Fig l) ? & We also used Southern blot hybridization of diEerent transgenic tissue DNAs to an Ig JH Probe to follow tumor progression in the transplant series. The Spleen Of the original donor (no. (Fig 3) . This finding SuEFsted the Presence of more than one major dominant clone in this animal. DNA from spleen and an affected l P P h node Of recipient R.1 showed both 4.3-and 3 -b rearranged bands, with41PPh node DNA containing only a faint germline band. Splenic DNA of R.2 lacked the 4.3-and 3-kb rearranged bands but showed two bands of a p p r o~a t e h ' 6.5 and 4 kb. Splenic DNA from animals R.1-1, 1-2, and 1-3 exhibited the same pattern as seen in the donor R.l (Fig 3) . Recipients of R.l-1 BM (animals R.1-1-1 and 1-1-2) had a prominent 4.3-kb band and a weak 3-kb band (Fig 3) . The lack of novel rearranged bands suggests that the clone containing the marker chromosome originated from the trisomy 12 clone.
The second transplant donor (no. 623-844-1037) had only one abnormal clone, containing an extra chromosome 12 in 10% of its leukemic cells ( Table 1) . Spleen DNA, however, exhibited at least seven rearranged bands with a J, probe (data not shown). Consistent with this finding, transplanted ahimals S.1-1, 1-2, and 2-3 (all primary recipients) showed six different cytogenetic clones, including the trisomy 12 clone (Fig 1) . Clones characterized by trisomies 10 and 12 and by trisomies 9 and 17 were found in more than one of the recipients and were presumably present as a minority, undetected clone in the original donor mouse. The trisomy 9 and 17 clone appeared to have a selective advantage in transplanted cells because it was present in all the transplanted animals of this series, ie, in both recipients of S.1-1 BM (animals 3-5 and 3-6), and as the dominant clone in both recipients of S.l-2 BM (animals S.4-7 and 4-8; Figs 1  and 2F) .
Thus, Southern blot analysis of the BM transplant series suggested distinct clonal patterns, and supported the presumed presence of unrelated clones, as seen cytogenetically.
The cytogenetics studies we have described above were based on leukemic samples taken from animals in late to very advanced stages of the disease. It was possible that the karyotype changes detected were present early in the disease and, together with the BCR/ABL gene product, were jointly responsible for the development of overt leukemia. Alternatively, their appearance could have been associated predominantly with disease progression. To investigate these possibilities, we examined the karyotype of mice early in the development of leukemia. For this purpose, a breeding line of animals progeny was obtained. New transgenic founders were made an extra chromosome l2 and 14 in a seiSnd c1one (Fig**) tSource of lymphoblasts. *Age at which animal was killed with terminal disease. §Animal had evolving lymphoblastic leukemia at death, with no lymph node but some marrow involvement. IlAnimal was diagnosed with lymphoblastic lymphoma, with apparent soft tissue involvement. progeny, and so on.
founded by mouse no. 623 was used. These animals showed an average age of death due to overt leukemia similar to that found in the other P190 BCR/ABL transgenic mice.
The appearance of BCR/ABL-expressing cells in PB was taken as a measure for the development of leukemia, and trial samples were taken from a test group to determine the earliest appearance of such cells in the circulation (data not shown). PB samples of 3 pL were drawn at regular intervals 
DISCUSSION
Previous experiments suggested that the activated BCR/ ABL oncogene was the primary factor causing LL in our transgenic mice.'" We can assume that the presence of the activated oncogene in many lymphoid cells would lead to multiple leukemias in single mice. Our present results support those concepts. The prime role of BCR/ABL in causing leukemia was supported by the early leukemia studies ( Table 3) . Only one of 10 animals had chromosomal abnormalities and none showed clonal growth. Later-stage leukemias, including those with large numbers of leukemic cells, showed many normal metaphases (39% of the total scored) and 8 of the 15 animals with chromosome abnormalities showed some normal metaphases (Tables 2 and 4) . These findings are a strong argument for the expansion of a pool of early leukemic cells that have BCR/ABL as a sole mutation. However, we can not exclude the possibility that cooperation between BCR/ABL and other oncogenes is necessary to generate overt leukemia. Such oncogenes could have been activated by mutations, not visible cytogenetically, of a similar form to structural alterations of the p53 gene present in more advanced stages of CML.2'.24
The idea of a multiple origin of the leukemia is supported by the transplantation of the BM of donor no. 623-844-1037, which gave rise, in different recipients, to independent clones characterized by IgH gene change or abnormal chromosome number. Other animals also showed evidence for independently derived leukemic clones. These multiple clones probably reflected the development of separate leukemias from different BCR/ABL-transformed lymphoid cells in single mice. Further cytogenetidgenetic-based progression of these clones, and their competition with each other, could be expected. There was no evidence of a common, specific cytogenetic change that was essential for the development of leukemias.
A high frequency of chromosome aneuploidy was noted in the advanced leukemias. The four cells showing gain of a different chromosome in the early leukemic mouse no. 1118 (Table 3) one of the common trisomies found in advanced leukemia in other P190 BCR/ABL mice.
The chromosome changes tended to be nonrandom in occurrence (Table 4) . Most prominent was the acquisition of extra copies 10, 12, 14, and 17, either alone or in combination. The gain of chromosomes 10, 12, and 17 was also found in the second BM transplant series (Fig l) , although the original donor showed only trisomy 12 in 10% of its cells. The first BM transplant series showed gain of chromosomes 12 and 14. The chromosomes involved in these nonrandom gains carry a number of loci known to be associated with cancer, cell growth, and development. Chromosome 10 carries the Steel locus, the bcr gene, the myb proto-oncogene,Ahi-I (a site of MoMuLV integration in Abelson murine leukemia virus-induced pre-B-cell lym- Table 3 . Karyotype of BCR/ABL P190 Mice Killed at 19 Days phomas), fin, ros-I, and Bruf" Mouse chromosome 10 exhibits four main regions of synteny with human chromosomes: 6q, 10, 12q, and 21q." Mouse chromosome 12 contains several MoMuLV integration sites, as well as the fos proto-oncogene, the transforming growth factor-P3 (TGF-P3) locus, N-myc, L-mycl, and the Ig heavy chain locus. This chromosome has main regions homologous to human chromosomes 2p (N-MYC) and 14q (TGF-P3, FOS, IgH). Mouse chromosome 14 also contains MoMuLV integration sites, the T-cell receptor-a (TCR-a) and -S loci and the Rb-1 gene, and has synteny with human chromosomes 10, 13q (RB-l), and 14q (TCR-cu and -S). Finally, mouse chromosome 17 has MoMuLV integration sites, the Pim-1 gene, tumor necrosis factor-a (TNF-a) and -P, the H-2 complex, and shows significant homology with human chromosome 6p (PIM, TNF-a, TNF-P, HLA). 26.27 How do these data compare with chromosome abnormalities found in human ALL? The leukemic cells of patients were the most obvious of these. This correlation between findings in the two species could indicate the presence of genes on these chromosomes, such as those described above, and others yet unidentified that are associated with an increase in proliferative potential. Structural changes are found in approximately one-third of human ALL patients. Specific translocations include the t(9;22), which is found in 2% to 6% of childhood and 19% to 30% of adult cases when leukemia is diagnosed. Chromosome abnormalities, in addition to the Ph chromosome, tend to be variable.I6 In this respect, the nonrandom chromosome changes and clonal evolution of our BCR/ABL P190 mice is more comparable with the nonrandom chromosome changes of human blast-phase CML.I6 It has been argued that the initial development of Ph-positive CML in humans is unrelated to the presence of the Ph chromo~ome,'~*'~ and that a primary Ph-negative leukemic clone(s) has an increased susceptibility, of an unknown nature, to acquire chromosomal abnormalities. This instability leads to the t(9;22) translocation and CML develops. The data described in this study provide no support for such model. In our mice, it is clear that expression of BCR/ABL precedes the development of chromosome abnormalities.
Cytogenetic variation is a marked feature of most forms of cancer, particularly their advanced stages, and is interpreted as a consequence of neoplasia. It has been postulated that the basic defect in Ph-positive CML lies in discordant maturation of cytoplasm and nucleus that results directly or indirectly from action of the BCR/ABL protein.29 Discordant maturation of cytoplasm and nucleus is likely to disrupt regulation of the cell cycle leading to nondisjunction and aneuploidy. Evidence that BCR/ABL disrupts cell cycle regulation also comes from experiments with the (murine) 32D cell line, which, when infected with an active BCR/ABL retroviral construct, shows an increase in cell size and a striking increase in the percentage of cells in the G2/M phase of the cell cycle. 30 Our results suggest that BCR/ABL expression is the prime event initiating Ph-positive leukemia and that cytogenetidgenetic instability, which sets the stage for additional mutations and progression of the leukemia, is either an indirect effect of this prime event or a direct effect of continued BCR/ABL expression.
